Agenus Inc
Veridion Score
BETAMEDIUM CONF · 5/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is AGEN moving today?
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
AGEN overview
Related filings and maps
Congress activity in AGEN
No receipt-qualified Congressional disclosure is present for AGEN in the cached public ledger.
AGEN contract awards, year to date.
Public federal awards linked to this ticker.
AGEN lobbying filings, year to date.
Registered lobbying filings matched to Agenus Inc.